BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash. , May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2022 financial results will be released after market close on Monday, May 9 th.

BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022

A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy.

BioLife: Can This Company Successfully Turn Around?

BOTHELL, Wash. , April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced that its Audit Committee (the "Committee") approved the engagement of Grant Thornton LLP ("Grant Thornton") as the Company's new independent registered public accounting firm, effective April 6, 2022.

BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP

BOTHELL, Wash. , March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and biopharma markets, announced today that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K").

BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing

BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K").

BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K

BOTHELL, Wash. , March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided additional details on its growth expectations for the Company's SciSafe®  biostorage services platform.

BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market

One of its acquired companies, Sterling, could not cope with the rapidly rising demand and this generated substantial one-off costs, marring the figures.

Temporary Setbacks At BioLife

BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced Mike Rice, Chairman and CEO, Rod de Greef, President and COO, and Troy Wichterman, CFO, are scheduled to present at both the Cowen and KeyBanc Investor Conferences in March 2022.

BioLife Solutions to Attend and Present at Upcoming Investor Conferences

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BOTHELL, Wash. , Feb. 28, 2022 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced unaudited financial results for the three and 12 months ended December 31, 2021 and introduced 2022 revenue guidance.

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results

BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2021 financial results will be released after market close on Monday, February 28 th.

BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022

PetIQ

PETQ vs. BLFS: Which Stock Is the Better Value Option?

PETQ or BLFS: Which Is the Better Value Stock Right Now?

Henderson, Nevada, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has finalized a definitive agreement (the “Agreement”) with Health Box LLC towards the 100% acquisition of the Arizona-based orthomolecular medicine and natural health products company.

BioLife Sciences Inc. (OTC Markets: BLFE) Announced Today That the Company Has Finalized a Definitive Agreement With Health Box LLC for the 100% Acquisition of the Orthomolecular Medicine and Natural Health Products Company

Incyte

Seagen

Try your hand at morphing science and business for a great investment opportunity in biotech.

Best Biotech Stocks to Invest in Now

BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced preliminary revenue for the fourth quarter and full year 2021.

BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020

BOTHELL, Wash., Jan. 4, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an extended collaboration with Seattle Children's Therapeutics, a venture at Seattle Children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children.

BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing

BioLife Solution is enjoying robust growth years over years.

BioLife: Poised For Growth

BOTHELL, Wash., Dec. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced a partnership with UNICEF to extend thermal stability of temperature-sensitive COVID-19 vaccines in developing communities in Africa, the Middle East and South America where limited power infrastructure and extreme environmental conditions make it difficult for most ULT freezers to remain operational.

UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines

BOTHELL, Wash., Nov. 17, 2021 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced it has ranked 353 in the 27th annual Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

BOTHELL, Wash., Nov. 15, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, today announced that it was named to Inc. Magazine's inaugural list of the 250 best-led companies in the United States.

BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies

BioLife Solutions, Inc. (BLFS) CEO Mike Rise on Q3 2021 Earnings Conference Call -Earnings Call Transcript

BOTHELL, Wash., Nov. 11, 2021 /PRNewswire/ --  BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and nine months ended September 30, 2021.

BioLife Solutions Announces Third Quarter 2021 Financial Results

BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.

BioLife Solutions Announces Executive Management Changes

BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2021 financial results will be released after market close on Thursday, November 11 th.

News for BioLife Solutions Stock (BLFS)